Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs
April 19, 2012 02:00 ET
|
Idenix Pharmaceuticals
IDX719 Demonstrates Pan-Genotypic Activity at Single Doses in HCV-Infected Patients Achieving Greater Than 3 log10 Viral Load Reductions in the 100 mg Dose Group Across Genotypes 1, 2 and 3;...